Response Genetics, Inc. (RGDX) Announces New President to Assist in Execution of Business Strategy and Operations

QualityStocks would like to highlight Response Genetics Inc. (NASDAQ: RGDX). The company is focused on the development and sale of molecular diagnostic tests for cancer. RGI’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. In addition to diagnostic testing services, the company generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry.

In the company’s news yesterday,

Response Genetics announced the appointment of Christine Meda as the company’s president, replacing Kathleen Danenberg, who will continue to act as CEO.

Meda’s nearly 30 years of experience in strategic partnering, operations, and marketing for Response Genetics will fuel her ability to help in the execution of the company’s strategy and operations on a day-to-day basis.

“I am pleased to be joining Response Genetics, a company with a unique platform technology and differentiated product offering. I look forward to applying my skills and experience knowing that I am not only providing value to the company and its shareholders, but helping improve the diagnostic information used to treat people with cancer,” Meda stated in the press release.

She previously served as CEO of early-stage molecular diagnostics company Arcxis Biotechnologies; founded and is president of RxDxLink, a consulting service for biotechnology companies; president and COO for early-stage cancer diagnostics company Diamics Inc.; as well as served several other industry-related positions.

“With her strong background in the diagnostics industry, Christine’s strategic vision and considerable business experience have helped companies successfully develop, launch and market products,” CEO Danenberg stated. “And with our current growth rate in the double digits, her addition to the senior management team will help Response Genetics expand its market and realize its growth potential.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.